Conventional and sustained-release valproate in children with newly diagnosed epilepsy: A randomized and crossover study comparing clinical effects, patient preference and pharmacokinetics

European Journal of Clinical Pharmacology

Volumn 62, Issue 10, 2006, Pages 805-815

  Herranz, José L ^a   Arteaga, Rosa ^a   Adín, Javier ^a   Armijo, Juan A ^a  

^a HOSPITAL UNIVERSITARIO MARQUÉS DE VALDECILLA   (Spain)

Author keywords

Anticonvulsants; Children; Efficacy; Pharmacokinetics; Sustained release valproate

Indexed keywords

VALPROIC ACID;

ABDOMINAL PAIN; ABNORMALLY HIGH SUBSTRATE CONCENTRATION IN BLOOD; ADOLESCENT; AGE DISTRIBUTION; AGGRESSIVENESS; ALLOPATHY; AMINOTRANSFERASE BLOOD LEVEL; AMNESIA; ARTHRALGIA; ARTICLE; CHILD; CLINICAL ARTICLE; CLINICAL TRIAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DISEASE DURATION; DROWSINESS; DRUG BLOOD LEVEL; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG TOLERANCE; ENURESIS; FATIGUE; FEMALE; FOCAL EPILEPSY; GENERALIZED EPILEPSY; HAIR DISEASE; HEADACHE; HUMAN; INCREASED APPETITE; LEARNING DISORDER; MALE; MONOTHERAPY; NAUSEA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RESTLESSNESS; SEX RATIO; SIDE EFFECT; STATISTICAL SIGNIFICANCE; SUSTAINED DRUG RELEASE; TABLET; TREATMENT DURATION; TREMOR; VOMITING; WEIGHT GAIN;

ADOLESCENT; ANTICONVULSANTS; CHILD; CHILD, PRESCHOOL; CHRONIC DISEASE; CROSS-OVER STUDIES; DATA INTERPRETATION, STATISTICAL; DELAYED-ACTION PREPARATIONS; DRUG ADMINISTRATION SCHEDULE; EPILEPSY, GENERALIZED; FEMALE; FLUORESCENCE POLARIZATION IMMUNOASSAY; HUMANS; MALE; PATIENT SATISFACTION; SPAIN; TABLETS; TIME FACTORS; TREATMENT OUTCOME; VALPROIC ACID;

EID: 33749468097     PISSN: 00316970     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00228-006-0175-2     Document Type: Article

References (29)

1. Bialer M (1992) Pharmacokinetic evaluation of sustained release formulations of antiepileptic drugs. Clinical implications. Clin Pharmacokinet 22:11-21
2. Davis R, Peters DH, McTavish D (1994) Valproic acid: a reappraisal of its pharmacological properties and clinical efficacy in epilepsy. Drugs 47:332-372
3. Perucca E (2002) Pharmacological and therapeutic properties of valproate: a summary after 35 years of clinical experience. CNS Drugs 16:695-714
4. Covanis A, Jeavons PM (1980) Once-daily sodium valproate in the treatment of epilepsy. Dev Med Child Neurol 22:202-204
5. Covanis A, Gupta AK, Jeavons PM (1981) Monotherapy with once-daily sodium valproate (Epilim). In: Dam M, Gram L, Penry JK (eds) Advances in epileptology. XII Epilepsy International Symposium. Raven Press, New York, pp 527-532
6. Gjerloff I, Arentsen J, Alving J, Secher BG (1984) Monodose versus 3 daily doses of sodium valproate: a controlled trial. Acta Neurol Scand 69:120-124
7. Rowan AJ, Overweg J, Meijer JWA (1981) Monodose therapy with valproic acid: 24 hour telemetric EEG and serum level studies. In: Dam M, Gram L, Penry JK (eds) Advances in epileptology. XII Epilepsy International Symposium. Raven Press, New York, pp 533-539
8. Schmidt D (1977) Fluctuation of dipropyl acetate plasma levels with one and three daily doses. Pharm Weekbl (Sci) 112:285-287
9. Stefan H, Burr W, Fichsel H, Fröscher W, Penin H (1984) Intensive follow-up monitoring in patients with once daily administration of sodium valproate. Epilepsia 25:152-160
10. Barre J, Berger Y (1989) Pharmacokinetics of a newly developed sustained release form of sodium valproate. In: Chadwick D (ed) Fourth international symposium on sodium valproate and epilepsy. Royal Society of Medicine Services, London, pp 178-184
11. Roberts D, Easter D, O'Bryan-Tear G (1996) Epilim chrono: a multidose, crossover comparison of two formulations of valproate in healthy volunteers. Biopharm Drug Dispos 17:175-182
12. Mimaki T, Fukuyama Y, Otsuka S et al (1991) Clinical pharmacokinetics of NIK-240, a new slow release granule of sodium valproate, in epileptic children (in Japanese). Shonika Rinsho (Tokyo) 44:183-201
13. Imaizumi T, Izumi T, Fukuyama Y (1992) A comparative clinical and pharmacokinetic study of a new slow-release versus conventional preparations of valproic acid in children with intractable epilepsy. Brain Dev 14:304-308
14. Brouwer OF, Pieters MSM, Edelbroek PM et al (1992) Conventional and controlled release valproate in children with epilepsy: a cross-over study comparing plasma levels and cognitive performance. Epilepsy Res 13:245-253
15. Despland PA (1994) A retrospective study of 113 epileptic patients treated with sustained-release valproate. Epilepsia 35 (Suppl 5):99-100
16. Wieser HG (1991) Comparison of valproate concentrations in human plasma, CSF and brain tissue after administration of different formulations of valproate or valpromide. Epilepsy Res 9:154-159
17. Ieiri I, Morioka T, Ichimiya T et al (1995) Pharmacokinetic study of valproic acid sustained-release preparation in patients undergoing brain surgery. Ther Drug Monit 17:6-11
18. Doughty J, Baker GA, Jacoby A, Lavaud V (2003) Compliance and satisfaction with switching from an immediate-release to sustained-release formulation of valproate in people with epilepsy. Epilepsy Behav 4:710-716
19. Mimaki T, Fukuyama Y, Abe T et al (1990) Clinical study of NIK-240, a new slow release granule of sodium valproate in epileptic children. Cross-over comparison to Depakine granule (in Japanese). Shonika Rinsho (Tokyo) 43:2970-2976
20. Rinnerthaler M, Luef G, Mueller J et al (2005) Computerized tremor analysis of valproate-induced tremor: a comparative study of controlled-release versus conventional valproate. Epilepsia 46:320-323
21. Thibault M, Blume WT, Saint-Hilaire JM, Zakhari R, Sommerville KW (2005) Divalproex extended-release versus the original divalproex tablet: results of a randomized, cross-over study of well-controlled epileptic patients with primary generalized seizures. Epilepsy Res 50:243-249
22. Cenraud B, Guyot M, Levy RH, Brachet-Liermain A, Morselli PL, Loiseau P (1981) Effect of dosage regimen on valproic acid plasma levels. In: Dam M, Gram L, Penry JK (eds) Advances in epileptology: XIIth epilepsy international symposium. Raven Press, New York, pp 549-553
23. Chadwick DW (1985) Concentration-effect relationships of valproic acid. Clin Pharmacokinet 10:155-163
24. Glauser TA, Pippenger CE (2000) Controversies in blood-level monitoring: reexamining its role in the treatment of epilepsy. Epilepsia 41(Suppl 8):6-15
25. Vajda F, Morris P, Drummer O, Bladin P (1976) In: Legg NJ (ed) Clinical and pharmacological aspects of sodium valproate in the treatment of epilepsy. Tunbridge Wells, Kent, pp 91-100
26. Gram L, Flachs H, Wurtz-Jorgensen A, Parnas J, Andersen B (1979) Sodium valproate, serum level and clinical effect in epilepsy: a controlled study. Epilepsia 20:303-312
27. Beydoun A, Sackellares JC, Shu V (1997) Safety and efficacy of divalproex sodium monotherapy in partial epilepsy: a double-blind, concentration-response design clinical trial. Neurology 48:182-188
28. Goggin T, Casey C, Callaghan N (1986) Serum levels of sodium valproate, phenytoin and carbamazepine and seizure control in epilepsy. Irish Med J 79:150-156
29. Turnbull DM, Rawlins MD, Weightman D, Chadwick DW (1983) Plasma concentrations of sodium valproate: their clinical value. Ann Neurol 14:38-42